Biocon Biologics Launches YESINTEK in U.S. for Autoimmune Diseases

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to patient care and biosimilar accessibility.

Biocon Biologics announced Monday the U.S. launch of its biosimilar drug, YESINTEK, targeting specific autoimmune diseases.

According to the company, YESINTEK is now accessible in the U.S., approved to treat conditions such as Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The drug is a biosimilar to Stelara.

CEO & MD Shreehas Tambe highlighted the launch as pivotal for expanding patient access to quality biosimilars, while North America head Josh Salsi emphasized a seamless treatment switch for healthcare providers.